편집
13,127
번
TENAYA, LUCERNE (2022): 두 판 사이의 차이
둘러보기로 이동
검색으로 이동
잔글
편집 요약 없음
잔글 (→결과) |
잔글편집 요약 없음 |
||
| 1번째 줄: | 1번째 줄: | ||
{{논문 | {{논문 | ||
|1=Efficacy, durability, and safety of intravitreal faricimab up to every 16w for nAMD (TENAYA and LUCERNE) : 2 randomised, double-masked, P3, non-inferiority trials<ref>Heier JS et al; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16w for nAMD (TENAYA and LUCERNE) : 2 randomised, double-masked, P3, non-inferiority trials. ''Lancet''. 2022 Feb 19;399(10326):729-740. [https://pubmed.ncbi.nlm.nih.gov/35085502/ 연결]</ref> | |1=Efficacy, durability, and safety of intravitreal faricimab up to every 16w for nAMD (TENAYA and LUCERNE) : 2 randomised, double-masked, P3, non-inferiority trials<ref>Heier JS et al; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16w for nAMD (TENAYA and LUCERNE) : 2 randomised, double-masked, P3, non-inferiority trials. ''Lancet''. 2022 Feb 19;399(10326):729-740. [https://pubmed.ncbi.nlm.nih.gov/35085502/ 연결]</ref> | ||
|2=습성 나이관련 황반변성에 대해 최대 16주마다 유리체강내 | |2=습성 나이관련 황반변성에 대해 최대 16주마다 유리체강내 [[파리시맙]]의 효과, 지속성 및 안정성 (TENAYA, LUCERNE) : 두 무작위, 이중 맹검, 3상, 비열등성 임상 시험 | ||
|3=Lancet | |3=Lancet | ||
|4= | |4= | ||